Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Elucidation of the IMiDs-Resistant Mechanism and Development of the Overcoming Drugs Inducing CRBN Independent G2/M Cell Cycle Arrest in Myeloma Cells

Ryo Uozaki, Shuji Aida, Takasi Yamagughi, Tomofumi Yamamoto, BPharm, Sho Kashiwazaki, Hiroshi Yanagawa, Daiju Ichikawa, Maiko Matsushita, Yutaka Hattori

Blood (2018) 132 (Supplement 1): 4451.

https://doi.org/10.1182/blood-2018-99-115909

Published: 2018

Journal Articles

Immunomodulatory Effects of Proteasome Inhibitors in Multiple Myeloma

Sho Kashiwazaki, Satoshi Kamiko, Ryo Uozaki, Tomofumi Yamamoto, BPharm, Daiju Ichikawa, Yutaka Hattori, Maiko Matsushita, Maki Hirao, Hisako Kunieda, Kohei Yamazaki

Blood (2018) 132 (Supplement 1): 1946.

https://doi.org/10.1182/blood-2018-99-115894

Published: 2018

Journal Articles

Understanding the Role of Extracellular Vesicles in Lenalidomide-Resistance Multiple Myeloma

Tomofumi Yamamoto, BPharm, Nobuyoshi Kosaka, PhD, Ochiya Takahiro, PhD, Yutaka Hattori

Blood (2018) 132 (Supplement 1): 1887.

https://doi.org/10.1182/blood-2018-99-115730

Published: 2018

Journal Articles

A Novel Phthalimide-Derivative, TC11, Induced G2/M Arrest and Apoptosis of High-Risk Myeloma Cells By Interacting with Nucleophosmin1 and α-Tubulin, but Not By Binding to Celeblon

Misa Nakamura, Daiju Ichikawa, PhD, Shuji Aida, Nahoko Hashimoto, Wakana Murota, Ryo Uozaki, Mikio Okayama, MD, Kota Fujimori, Yuko Yonemura, Noriko Tabata, PhD, Hiroshi Yanagawa, PhD, Maiko Matsushita, MD PhD, Yutaka Hattori, MD PhD

Blood (2017) 130 (Supplement 1): 5377.

https://doi.org/10.1182/blood.V130.Suppl_1.5377.5377

Published: 2017

Journal Articles

10 Years History of Cost-Effectiveness for 209 Newly Diagnosed Multiple Myeloma Patients at a Single-Institute in Japan

Kenshi Suzuki, MD PhD, Tomofumi Yamamoto, Masahiro Ikeda, MD, Tomomi Takei, MD, Nobuhiro Tsukada, MD PhD, Tadao Ishida, MD PhD, Arimi Ueda, Daiju Ichikawa, PhD, Maiko Matsushita, MD PhD, Yutaka Hattori, MD PhD

Blood (2016) 128 (22): 5620.

https://doi.org/10.1182/blood.V128.22.5620.5620

Published: 2016

Journal Articles

Komaroviquinone-Derivatives, Revealed Anti-Tumor Effect on High-Risk Multiple Myeloma Cells In Vitro as Well as In Vivo

Mariko Sato, Kota Fujimori, Shotaro Kitabatake, Mikio Okayama, MD, Daiju Ichikawa, PhD, Yutaka Suto, PhD, Genji Iwasaki, PhD, Fumiyuki Kiuchi, PhD, Takashi Yamaguchi, Arimi Ueda, Shuji Aida, Hitomi Nakayama, MD, Maiko Matsushita, MD PhD, Yutaka Hattori, MD PhD

Blood (2016) 128 (22): 2100.

https://doi.org/10.1182/blood.V128.22.2100.2100

Published: 2016

Journal Articles

Drug Design for Overcoming High-Risk Myeloma and Identification of Novel Binding Proteins to Immune-Modulatory Drugs

Masashi Hozumi, Daiju Ichikawa, PhD, Maiko Matsushita, MD PhD, Eriko Kamiyama, Hiroshi Yanagawa, PhD, Noriko Tabata, PhD, Shotaro Kitabatake, Arimi Ueda, Takashi Yamaguchi, Mariko Sato, Yutaka Hattori, MD PhD

Blood (2015) 126 (23): 1800.

https://doi.org/10.1182/blood.V126.23.1800.1800

Published: 2015

Journal Articles

Development of a Novel Phthalimide Derivative, Preclinical Effects on High-Risk Myeloma Cells and Osteoclasts

Yutaka Hattori, MD PhD, Maiko Matsushita, MD PhD, Noriko Tabata, Hirokazu Shiheido, Hiroshi Yanagawa, PhD, Arimi Ueda, Masashi Hozumi, Shotaro Kitabatake, Daiju Ichikawa

Blood (2014) 124 (21): 5718.

https://doi.org/10.1182/blood.V124.21.5718.5718

Published: 2014

Journal Articles

Codon 72 Polymorphism Of TP53 Gene Is a Novel Prognostic Marker For Thalidomide Therapy In Multiple Myeloma

Yutaka Hattori, MD, PhD, Yurika Ikeda, Yuya Suzuki, Daiju Ichikawa, PhD, Maiko Matsushita, MD, PhD

Blood (2013) 122 (21): 1891.

https://doi.org/10.1182/blood.V122.21.1891.1891

Published: 2013

Journal Articles

Impact Of Novel Agents To The Additional-Chromosomal Abnormalities In Patients With Multiple Myeloma

Kenshi Suzuki, MD, PhD, Yu Abe, Kanji Miyazaki, Rieko Sekine, MD, PhD, Nobuhiro Tsukada, MD, PhD, Yutaka Hattori, MD, PhD, Airi Hamano, Sumito Shingaki

Blood (2013) 122 (21): 3225.

https://doi.org/10.1182/blood.V122.21.3225.3225

Published: 2013

Journal Articles

TC11, a Novel Phthalimide Derivative, Directly Binds to NPM1 and Induced Apoptosis of High-Risk Myeloma Cells Via Centrosomal Disruption

Saito Sosei, Kana Yoshikawa, Noriko Tabata, PhD, Hiroshi Yanagawa, PhD, Tsukasa Oikawa, PhD, Wenlin Du, MD, PhD, Taketo Yamada, MD, PhD, Maiko Matsushita, MD, PhD, Junya Seki, Kaoru Tohyama, MD, PhD, Yutaka Hattori, MD, PhD

Blood (2012) 120 (21): 1841.

https://doi.org/10.1182/blood.V120.21.1841.1841

Published: 2012

Journal Articles

A Novel Anilinoquinazoline Derivative Inhibits Growth of High-Risk Myeloma Cells In Vivo and Regulates Differentiation of Osteoclasts

Yoshie Ozaki, Yuhei Naito, Hiroshi Yanagawa, PhD, Yuya Suzuki, Wenlin Du, MD, PhD, Taketo Yamada, MD, PhD, Koichi Matsuo, MD, PhD, Nobuhide Doi, PhD, Shiro Iijima, PhD, Maiko Matsushita, MD, PhD, Kayoko Tahara, PhD, Yutaka Hattori, MD, PhD

Blood (2010) 116 (21): 4076.

https://doi.org/10.1182/blood.V116.21.4076.4076

Published: 2010

Journal Articles

Hepatocyte Growth Factor-Producing Multiple Myeloma (HGF myeloma) Is a Distinct Clinical Entity and Needs for Molecular Targeted Therapy.

Yutaka Hattori, Shin-ichiro Okamoto, MD, PhD, Wenlin Du, Taketo Yamada, Naoki Shimada, Kunio Matsumoto, Morihiko Sagawa, Yasuo Ikeda

Blood (2008) 112 (11): 1717.

https://doi.org/10.1182/blood.V112.11.1717.1717

Published: 2008

Journal Articles

NK4, an antagonist of hepatocyte growth factor (HGF), inhibits growth of multiple myeloma cells: molecular targeting of angiogenic growth factor

Wenlin Du, Yutaka Hattori, Taketo Yamada, Kunio Matsumoto, Toshikazu Nakamura, Morihiko Sagawa, Takemi Otsuki, Takako Niikura, Toshihiro Nukiwa, Yasuo Ikeda

Blood (2006) 109 (7): 3042–3049.

https://doi.org/10.1182/blood-2006-02-003103

Published: 2006

Journal Articles

5HPP-33, a Novel Tubulin-Polymerization Inhibitor Derived from Thalidomide, Directly Inhibits Proliferation and Induces Apoptosis of Human Multiple Myeloma Cells.

Toyotaka Iguchi, MD, Sawako Oda-Nakazato, MD, Tomomi Noguchi, MS, Yuichi Hashimoto, PhD, Yutaka Hattori, MD, Taketo Yamada, MD, Yasuo Ikeda, MD, Masahiro Kizaki, MD

Blood (2005) 106 (11): 1586.

https://doi.org/10.1182/blood.V106.11.1586.1586

Published: 2005

Journal Articles

NK4, an Antagonist of Hepatocyte Growth Factor (HGF), Inhibits Growth of Multiple Myeloma Cells In Vitro and In Vivo : A Mouse Model for Molecular Targeting of Angiogenic Growth Factor.

Yutaka Hattori, MD, Wenlin Du, PhD, Taketo Yamada, MD, Kunio Matsumoto, PhD, Toshikazu Nakamura, MD, Takemi Otsuki, MD, Takako Niikura, PhD, Toshihiro Nukiwa, MD, Yasuo Ikeda, MD

Blood (2004) 104 (11): 637.

https://doi.org/10.1182/blood.V104.11.637.637

Published: 2004

Journal Articles

Targeting NF-κB and Induction of Apoptosis by Dehydroxymethylepoxyquinomicin (DHMEQ) in Multiple Myeloma Cells.

Yoshitaka Miyakawa, MD, Kanoko Kohmura, MD, Kaori Saito, Hiroshi Yoshida, Asako Ikejima, Yutaka Hattori, MD, Yasuyuki Ohnishi, PhD, Masato Nakamura, MD, Yasuo Ikeda, MD, Kazuo Umezawa, PhD, Masahiro Kizaki, MD

Blood (2004) 104 (11): 3393.

https://doi.org/10.1182/blood.V104.11.3393.3393

Published: 2004

Journal Articles

Bone morphogenetic protein-2 induces apoptosis in human myeloma cells with modulation of STAT3

Chiharu Kawamura, Masahiro Kizaki, Kenji Yamato, Hideo Uchida, Yumi Fukuchi, Yutaka Hattori, Takeyoshi Koseki, Tatsuji Nishihara, Yasuo Ikeda

Blood (2000) 96 (6): 2005–2011.

https://doi.org/10.1182/blood.V96.6.2005

Published: 2000

Journal Articles

Restoration of Retinoid Sensitivity by MDR1 Ribozymes in Retinoic Acid–Resistant Myeloid Leukemic Cells

Hiromichi Matsushita, Masahiro Kizaki, Hiroyuki Kobayashi, Hironori Ueno, Akihiro Muto, Nobuyuki Takayama, Norihiro Awaya, Kentaro Kinjo, Yutaka Hattori, Yasuo Ikeda

Blood (1998) 91 (7): 2452–2458.

https://doi.org/10.1182/blood.V91.7.2452

Published: 1998

NARROW

Elucidation of the IMiDs-Resistant Mechanism and Development of the Overcoming Drugs Inducing CRBN Independent G2/M Cell Cycle Arrest in Myeloma Cells

Immunomodulatory Effects of Proteasome Inhibitors in Multiple Myeloma

Understanding the Role of Extracellular Vesicles in Lenalidomide-Resistance Multiple Myeloma

A Novel Phthalimide-Derivative, TC11, Induced G2/M Arrest and Apoptosis of High-Risk Myeloma Cells By Interacting with Nucleophosmin1 and α-Tubulin, but Not By Binding to Celeblon

10 Years History of Cost-Effectiveness for 209 Newly Diagnosed Multiple Myeloma Patients at a Single-Institute in Japan

Komaroviquinone-Derivatives, Revealed Anti-Tumor Effect on High-Risk Multiple Myeloma Cells In Vitro as Well as In Vivo

Drug Design for Overcoming High-Risk Myeloma and Identification of Novel Binding Proteins to Immune-Modulatory Drugs

Development of a Novel Phthalimide Derivative, Preclinical Effects on High-Risk Myeloma Cells and Osteoclasts

Codon 72 Polymorphism Of TP53 Gene Is a Novel Prognostic Marker For Thalidomide Therapy In Multiple Myeloma

Impact Of Novel Agents To The Additional-Chromosomal Abnormalities In Patients With Multiple Myeloma

TC11, a Novel Phthalimide Derivative, Directly Binds to NPM1 and Induced Apoptosis of High-Risk Myeloma Cells Via Centrosomal Disruption

A Novel Anilinoquinazoline Derivative Inhibits Growth of High-Risk Myeloma Cells In Vivo and Regulates Differentiation of Osteoclasts

Hepatocyte Growth Factor-Producing Multiple Myeloma (HGF myeloma) Is a Distinct Clinical Entity and Needs for Molecular Targeted Therapy.

NK4, an antagonist of hepatocyte growth factor (HGF), inhibits growth of multiple myeloma cells: molecular targeting of angiogenic growth factor

5HPP-33, a Novel Tubulin-Polymerization Inhibitor Derived from Thalidomide, Directly Inhibits Proliferation and Induces Apoptosis of Human Multiple Myeloma Cells.

NK4, an Antagonist of Hepatocyte Growth Factor (HGF), Inhibits Growth of Multiple Myeloma Cells In Vitro and In Vivo : A Mouse Model for Molecular Targeting of Angiogenic Growth Factor.

Targeting NF-κB and Induction of Apoptosis by Dehydroxymethylepoxyquinomicin (DHMEQ) in Multiple Myeloma Cells.

Bone morphogenetic protein-2 induces apoptosis in human myeloma cells with modulation of STAT3

Restoration of Retinoid Sensitivity by MDR1 Ribozymes in Retinoic Acid–Resistant Myeloid Leukemic Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only